Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess the efficacy and safety of nemolizumab (CIM331), a humanized antibody against interleukin-31 receptor A, in the treatment of atopic dermatitis. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments to receive subcutaneous nemolizumab (at a dose of 0.1 mg, 0.5 mg, or 2.0 mg per kilogram of body weight) or placebo every 4 weeks or an exploratory dose of 2.0 mg of nemolizumab per kilogram every 8 weeks. The primary end point was the percentage improvement from baseline in the score on the pruritus visual-analogue scale (on which a negative change indicates improvement) at week 12. Secondary end points included changes in the score on the Eczema Area and Severity Index (EASI, on which a negative change indicates improvement), and body-surface area of atopic dermatitis. RESULTS: Of 264 patients who underwent randomization, 216 (82%) completed the study. At week 12, among the patients who received nemolizumab every 4 weeks, changes on the pruritus visual-analogue scale were -43.7% in the 0.1-mg group, -59.8% in the 0.5-mg group, and -63.1% in the 2.0-mg group, versus -20.9% in the placebo group (P<0.01 for all comparisons). Changes on the EASI were -23.0%, -42.3%, and -40.9%, respectively, in the nemolizumab groups, versus -26.6% in the placebo group. Respective changes in body-surface area affected by atopic dermatitis were -7.5%, -20.0%, and -19.4% with nemolizumab, versus -15.7% with placebo. Among the patients receiving nemolizumab every 4 weeks, treatment discontinuations occurred in 9 of 53 patients (17%) in the 0.1-mg group, in 9 of 54 (17%) in the 0.5-mg group, and in 7 of 52 (13%) in the 2.0-mg group, versus in 9 of 53 (17%) in the placebo group. CONCLUSIONS: In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase IIa study, the anti-IL-31Rα antibody nemolizumab led to a significant decrease in the pruritus sensation”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
In the citing paper
“but the overall clinical inflammation as evaluated by the body surface area (BSA), EASI and IGA scorings did not improve significantly at this time point189.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [189]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586 · cited 1×
“Japan 16 (30) 16 (30) 16 (30) 16 (31) 15 (29)”
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Bieber, T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra074081 · Cited by 1,780
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224 · cited 3×
“Not related to atopic dermatitis 1 (2) 1 (2) 0 1 (2) 1 (2)”
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Self-citationIL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Muller, A., Lauerma, A. I., Pivarcsi, A., Soto, H., Kemeny, L., Alenius, H., Dieu-Nosjean, M.-C., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,005
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981 · cited 1×
“4 22 (42) 18 (34) 25 (46) 25 (48) 22 (42)”
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885 · cited 1×
“(%)† 8 (15) 9 (17) 6 (11) 5 (10) 7 (13)”
Self-citationCevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., Kukova, G., Buhl, T., Ikoma, A., Buddenkotte, J., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.10.048 · Cited by 804 · cited 2×
“(%)† 7 (13) 11 (21) 10 (19) 11 (21) 9 (17)”
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Self-citation
Research works printed but not linked: 2
- Oyama S, Exp Dermatol
- Lichstein KL, 2006, Sleep, 29, 232
Cited by
Items 101–200 of 588
From Emollients to Biologicals: Targeting Atopic Dermatitis
Salvati, L., Cosmi, L., & Annunziato, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910381 · Cited by 93
Insights into atopic dermatitis gained from genetically defined mouse models
Nakajima, S., Nomura, T., Common, J., & Kabashima, K. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.014 · Cited by 86
Self-citationNew and emerging treatments for inflammatory itch
Erickson, S., Heul, A. V., & Kim, B. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.05.028 · Cited by 79
Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults
Barrett, A. M., Hahn-Pedersen, J. H., Kragh, N., Evans, E., & Gnanasakthy, A. (2019) · Patient · doi:10.1007/s40271-019-00373-y · Cited by 90
Pathophysiology and Treatment of Pruritus in Elderly
Chung, B. Y., Um, J., Kim, J. C., Kang, S. Y., Park, C. W., & Kim, H. O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010174 · Cited by 95
Radonjic‐Hoesli, S., Brüggen, M., Feldmeyer, L., Simon, H., & Simon, D. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00868-7 · Cited by 86
Atopic dermatitis guidelines: Diagnosis, systemic therapy, and adjunctive care
Sidbury, R., & Kodama, S. (2018) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2018.05.008 · Cited by 85
Daily Lifestyle and Inflammatory Skin Diseases
Sawada, Y., Saito‐Sasaki, N., Mashima, E., & Nakamura, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105204 · Cited by 90
The Itch-Scratch Cycle: A Review of the Mechanisms
Rinaldi, G. (2019) · Dermatology Practical & Conceptual · doi:10.5826/dpc.0902a03 · Cited by 82
Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease
Arnold, I. C., & Munitz, A. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01048-y · Cited by 87
Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children
Chovatiya, R., & Silverberg, J. I. (2019) · Children · doi:10.3390/children6100108 · Cited by 87
New and developing therapies for atopic dermatitis
Hajar, T., Gontijo, J. R. V., & Hanifin, J. M. (2018) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.20187682 · Cited by 68
Self-citationKwatra, S. G., Misery, L., Clibborn, C., & Steinhoff, M. S. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1390 · Cited by 78
Ravn, N. H., Ahmadzay, Z. F., Christensen, T. A., Larsen, H. H. P., Loft, N., Rævdal, P., Heegaard, S., Kolko, M., Egeberg, A., Silverberg, J. I., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.11.037 · Cited by 70
Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01741-z · Cited by 68
Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies
Nygaard, U., Vestergaard, C., & Deleuran, M. S. (2017) · Dermatology · doi:10.1159/000484406 · Cited by 74
Eosinophilic Dermatoses: Recognition and Management
Marzano, A. V., & Genovese, G. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00520-4 · Cited by 67
Kim, R. W., Lam, M., Abuabara, K., Simpson, E. L., & Drucker, A. M. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00837-w · Cited by 72
Systemic treatments for eczema: a network meta-analysis
Sawangjit, R., Dilokthornsakul, P., Lloyd-Lavery, A., Lai, N. M., Dellavalle, R. P., & Chaiyakunapruk, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013206.pub2 · Cited by 80
Biological therapies for atopic dermatitis: An update�(Review)
Deleanu, D., & Nedelea, I. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6989 · Cited by 62
Endotypes of atopic dermatitis
Fyhrquist, N., Yang, Y., Karisola, P., & Alenius, H. T. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.02.029 · Cited by 78
Ohanyan, T., Schoepke, N., Eirefelt, S., Hoey, G., Koopmann, W., Hawro, T., Maurer, M., & Metz, M. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2780 · Cited by 63
Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019
Simon, D., Wollenberg, A., Renz, H. E., & Simon, H. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000497383 · Cited by 75
Self-citationThe use of biologics for immune modulation in allergic disease
van de Veen, W., & Akdiş, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124607 · Cited by 67
“A phase II trial demonstrated that subcutaneous monthly treatment with nemolizumab significantly reduced the level of pruritus after 3 months in patients with moderate to severe AD (84).”
BackgroundKnobler, R., Arenberger, P., Arun, A., Assaf, C., Bagot, M., Berlin, G., Bohbot, A., Calzavara‐Pinton, P., Child, F. J., Cho, A., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16889 · Cited by 67
Xu, J., Wang, Y., Khoshdeli, M., Peach, M., Chuang, J.-C., Lin, J. H., Tsai, W., Mahadevan, S., Minto, W. C., Diehl, L. J., et al. (2022) · Hepatology · doi:10.1002/hep.32599 · Cited by 66
The Antipruritic Effect of Phototherapy
Legat, F. J. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00333 · Cited by 66
“In recent clinical trials, the IL-31Ra antagonist nemolizumab was capable of significantly reducing pruritus in AD (59) and in addition, improved atopic eczema.”
BackgroundInterleukin-31 and Pruritic Skin
Furue, M., & Furue, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091906 · Cited by 69
Self-citationWhat’s New in Atopic Dermatitis
Renert-Yuval, Y., & Guttman-Yassky, E. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2018.12.007 · Cited by 60
Miake, S., Tsuji, G., Takemura, M., Hashimoto‐Hachiya, A., Vu, Y. H., Furue, M., & Nakahara, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164053 · Cited by 61
“Since recent studies have shown that IL-31 and its inte act with IL-31RA play a crucial role the d velopm nt of AD [7,11], clarifying the regulatory mechanism of IL-31RA expression under Th2-deviated conditions is very useful for treating AD.”
BackgroundMethodSelf-citationImmunosensation: Neuroimmune Cross Talk in the Skin
Tamari, M., Heul, A. V., & Kim, B. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101719-113805 · Cited by 64
Silverberg, J. I., Pinter, A., Alavi, A., Lynde, C. W., Bouaziz, J., Wollenberg, A., Murrell, D. F., Alpizar, S., Laquer, V. T., Chaouche‐Teyara, K., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17218 · Cited by 60
Self-citationEmerging Biologic Therapies for the Treatment of Atopic Dermatitis
Alvarenga, J. M., Bieber, T. R. M., & Torres, T. R. (2024) · Drugs · doi:10.1007/s40265-024-02095-4 · Cited by 64
Igarashi, A., Katsunuma, T., Matsumura, T., Komazaki, H., for the Nemolizumab-JP04 Study Group, Takahashi, H., Miura, K., Horino, S., Yoshihara, S., Maeda, S., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad268 · Cited by 60
DUCA, E. D., He, H., Liu, Y., Pagan, A. D., David, E., Cheng, J., Carroll, B. E., Renert‐Yuval, Y., Bar, J., Estrada, Y. D., et al. (2023) · Allergy · doi:10.1111/all.15845 · Cited by 61
Exploring the Role of Staphylococcus Aureus Toxins in Atopic Dermatitis
Yoshikawa, F. S. Y., de Lima, J. F., Sato, M. N., Ramos, Y. Á. L., Aoki, V., & Orfali, R. L. (2019) · Toxins · doi:10.3390/toxins11060321 · Cited by 69
“Likewise, other monoclonal antibodies are under investigation, for example, nemolizumab (CIM331), a humanized antibody against the IL-31 receptor [93] (clinicaltrials.”
BackgroundTreatment-resistant prurigo nodularis: challenges and solutions
Kowalski, E. H., Kneiber, D., Valdebran, M., Patel, U., & Amber, K. T. (2019) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s188070 · Cited by 62
Prostanoids and leukotrienes in the pathophysiology of atopic dermatitis and psoriasis
Honda, T., & Kabashima, K. (2019) · International Immunology · doi:10.1093/intimm/dxy087 · Cited by 64
Self-citationCytokine modulation of atopic itch
Trier, A. M., & Kim, B. S. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.05.005 · Cited by 55
Biological Therapies for Atopic Dermatitis: A Systematic Review
Zhou, S., Qi, F., Gong, Y., Zhang, J., & Zhu, B. (2021) · Dermatology · doi:10.1159/000514535 · Cited by 52
Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.
Egeberg, A., Thyssen, J. P., & Wu, J. J. (2017) · PubMed · doi:10.1056/nejmc1704013 · Cited by 12
Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review
Tier, H. L., Balogh, E. A., Bashyam, A. M., Fleischer, A. B., Spergel, J. M., Masicampo, E. J., Kammrath, L. K., Strowd, L. C., & Feldman, S. R. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00500-4 · Cited by 54
Thymic Stromal Lymphopoietin in Cutaneous Immune-Mediated Diseases
Wang, S.-H., & Zuo, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698522 · Cited by 60
“Moreover, monoclonal antibodies targeting these cytokines have favorable functions in alleviating pruritus in AD patients (62, 63).”
BackgroundEnglish version of clinical practice guidelines for the management of atopic dermatitis 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17544 · Cited by 59
Petra, A. I., Tsilioni, I., Taracanova, A., Katsarou‐Katsari, A., & Theoharides, T. C. (2018) · Allergy and Asthma Proceedings · doi:10.2500/aap.2018.38.4105 · Cited by 57
Neuroimmune interactions in atopic and allergic contact dermatitis
Liu, A. W., Gillis, J. E., Sumpter, T. L., & Kaplan, D. H. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.03.013 · Cited by 60
Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines
Boguniewicz, M. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.031 · Cited by 55
The Challenge of Managing Atopic Dermatitis in the United States.
Feldman, S. R., Cox, L., Strowd, L. C., Gerber, R. A., Faulkner, S., Sierka, D., Smith, T. W., Cappelleri, J. C., & Levenberg, M. (2019) · PubMed · Cited by 61
Olomski, F., Fettelschoss, V., Jónsdóttir, S., Birkmann, K., Thoms, F., Marti, E., Bachmann, M. F., Kündig, T. M., & Fettelschoss‐Gabriel, A. (2019) · Allergy · doi:10.1111/all.14145 · Cited by 53
Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans
Nakajima, S., Tie, D., Nomura, T., & Kabashima, K. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155664 · Cited by 62
Self-citationBlockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
Orfali, R. L., & Aoki, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020577 · Cited by 58
Unravelling the pathophysiology of chronic kidney disease-associated pruritus
Schricker, S., & Kimmel, M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab200 · Cited by 51
Interactions of the immune and sensory nervous systems in atopy
Oetjen, L. K., & Kim, B. (2018) · FEBS Journal · doi:10.1111/febs.14465 · Cited by 55
A New Generation of Treatments for Itch
Fowler, E., & Yosipovitch, G. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3347 · Cited by 54
Interventions for chronic pruritus of unknown origin
Andrade, A., Kuah, C. Y., Martín-López, J. E., Chua, S., Shpadaruk, V., Sanclemente, G., & Franco, J. V. A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013128.pub2 · Cited by 65
Lacouture, M. E., Goleva, E., Shah, N. J., Rotemberg, V. M., Kraehenbuehl, L., Ketosugbo, K. F., Merghoub, T., Maier, T., Bang, A., Gu, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3431 · Cited by 55
Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions
Ruppenstein, A., Limberg, M. M., Loser, K., Kremer, A. E., Homey, B., & Raap, U. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.627985 · Cited by 57
“More recent findings have demonstrated that nemolizumab, an anti-IL-31RA antibody that binds to IL-31RA with subsequent inhibition of IL-31 signaling effectively relieves AD-associated pruritus (81, 82).”
BackgroundThe evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective
David, E., Ungar, B., Renert‐Yuval, Y., Facheris, P., DUCA, E. D., & Guttman‐Yassky, E. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14263 · Cited by 52
Molecular aspects of allergens in atopic dermatitis
Campana, R., Dzoro, S., Mittermann, I., Fedenko, E. S., Elisyutina, O. G., Khaitov, M. R., Karaulov, A. V., & Valenta, R. (2017) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000378 · Cited by 53
New and emerging targeted systemic therapies: a new era for atopic dermatitis
Lee, D. E., Clark, A. K., Tran, K. A., & Shi, V. Y. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1373736 · Cited by 52
Immune Dysregulation in the Pathogenesis of Atopic Dermatitis
Gavrilova, T. (2018) · Dermatitis · doi:10.1097/der.0000000000000340 · Cited by 49
Eosinophil-Related Disease and the Skin
Leiferman, K. M., & Peters, M. S. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.06.002 · Cited by 48
Advances in understanding of Netherton syndrome and therapeutic implications
Petrova, E., & Hovnanian, A. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1857724 · Cited by 51
What's new in the treatment of atopic dermatitis?
Dattola, A., Bennardo, L., Silvestri, M., & Nisticò, S. P. (2018) · Dermatologic Therapy · doi:10.1111/dth.12787 · Cited by 46
“…a 0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg dose every 4 weeks and showed a reduction in pruritus analogue scale, respectively, of 43.7, 59.8, 63.1%, changes in eczema area and severity index (EASI) score, respectively, of −23, −42.3, −40.9 (Fioranelli, Roccia, & Lotti, 2017; Ruzicka et al., 2017).”
BackgroundInfluentialCytokine-targeting biologics for allergic diseases
Lawrence, M. G., Steinke, J. W., & Borish, L. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.01.009 · Cited by 48
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)
Khoury, P., Akuthota, P., Ackerman, S. J., Arron, J. R., Bochner, B. S., Collins, M. H., Kahn, J., Fulkerson, P. C., Gleich, G. J., Gopal-Srivastava, R., et al. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0118-028r · Cited by 45
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
Yook, H. J., & Lee, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105164 · Cited by 51
Misery, L., Fortina, A. B., Hachem, M. E., Chernyshov, P. V., von Kobyletzki, L., Heratizadeh, A., Marcoux, D., Aoki, V., Zaniboni, M. C., Stalder, J. F., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16916 · Cited by 50
MRGPRX2 sensing of cationic compounds—A bridge between nociception and skin diseases?
Corbière, A., Loste, A., & Gaudenzio, N. (2020) · Experimental Dermatology · doi:10.1111/exd.14222 · Cited by 48
Furue, M., Hashimoto-Hachiya, A., & Tsuji, G. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-3003 · Cited by 44
Self-citationTherapeutic targeting of the IL-13 pathway in skin inflammation
Tubau, C., & Puig, L. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1858802 · Cited by 50
Schmelz, M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00167 · Cited by 47
“Only IL-31 would remain as mediator, mainly associated to itching rather than pain, which would be in line with human data on antipruritic effects of IL-31 receptor antibodies (36), but also the co-expression of the IL31 receptor and natriuretic peptide B in a subpopulation of dorsal root ganglion neurons (37).”
ResultInnovación en dermatitis atópica: de la patogenia a la terapéutica
Munera‐Campos, M., & Carrascosa, J. M. (2020) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2019.11.002 · Cited by 47
Kinugasa, E., Igawa, K., Shimada, H., Kondo, M., Funakoshi, S., Imada, N., Itami, N., Fukazawa, N., Takubo, R., Kawata, Y., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02047-2 · Cited by 49
Chronic itch: emerging treatments following new research concepts
Misery, L., Brenaut, E., Pierre, O., Garrec, R. L., Gouin, O., Lebonvallet, N., Abasq‐Thomas, C., Talagas, M., Gall‐Ianotto, C. L., Morin, C. B., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15672 · Cited by 47
New Insights and Treatments in Atopic Dermatitis
Saini, S., & Pansare, M. V. (2019) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2019.06.008 · Cited by 44
Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk
Szöllősi, A. G., Oláh, A., Lisztes, E., Griger, Z., & Tóth, B. I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.745658 · Cited by 43
“Nevertheless, Nemolizumab has been proven to be efficacious in the treatment of AD (Ruzicka et al., 2017), which hints that in humans IL-31 acts indirectly to induce itch.”
BackgroundInfluentialResearch Techniques Made Simple: Itch Measurement in Clinical Trials
Erickson, S. P., & Kim, B. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.004 · Cited by 47
Severe Atopic Dermatitis in Children
Huang, E., & Ong, P. Y. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0788-4 · Cited by 41
Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches
Baye, T. M., Afanador, Y., Johansson, E., Proper, S. P., Bernstein, J. A., Rothenberg, M. E., & Hershey, G. K. K. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08787-5 · Cited by 45
“The IL-31 receptor plays a role in the occurrence of pruritus in AD, and a recent phase 2, randomized, double-blind, placebo-controlled, 12-week trial was conducted on 264 adults with moderate to severe AD who received subcutaneous nemolizumab [201].”
BackgroundResultSidbury, R., Alpizar, S., Laquer, V., Dhawan, S., Abramovits, W., Loprete, L., Krishnaswamy, J. K., Ahmad, F., Jabbar-Lopez, Z., & Piketty, C. (2022) · Dermatology and Therapy · doi:10.1007/s13555-021-00678-7 · Cited by 38
Ko, K., Kim, H. J., Ho, P., Lee, S. O., Lee, J., Min, C.-R., Kim, Y. C., Yoon, J., Park, E., Kwon, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01855 · Cited by 41
Treatment of Atopic Dermatitis with Biologic Drugs
Fabbrocini, G., Napolitano, M., Megna, M., Balato, N., & Patruno, C. (2018) · Dermatology and Therapy · doi:10.1007/s13555-018-0258-x · Cited by 43
New and Emerging Therapies for Pediatric Atopic Dermatitis
Nguyen, H. L., Anderson, K., & Tollefson, M. M. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00342-w · Cited by 41
Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms
Chaowattanapanit, S., Choonhakarn, C., Salao, K., Winaikosol, K., Julanon, N., Wongjirattikarn, R., Foocharoen, C., & Sompornrattanaphan, M. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05621 · Cited by 40
Topical therapy of atopic dermatitis with a focus on pimecrolimus
Luger, T. A., Paller, A. S., Irvine, A. D., Sidbury, R., Eichenfield, L. F., Werfel, T., & Bieber, T. R. M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17272 · Cited by 43
Consensus Update for Systemic Treatment of Atopic Dermatitis
Lee, J. H., Kim, J. E., Park, G., Bae, J. M., Byun, J. Y., Shin, M. K., Han, T. Y., Hong, S., Jang, Y. H., Kim, H. O., et al. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.6.497 · Cited by 39
Steinhoff, M. S., Oaklander, A. L., Szabó, I. L., Ständer, S., & Schmelz, M. (2019) · Pain · doi:10.1097/j.pain.0000000000001551 · Cited by 45
Pruritus in Cutaneous T-Cell Lymphoma and Its Management
Serrano, L., Martínez‐Escala, M. E., Zhou, X. A., & Guitart, J. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.011 · Cited by 42
Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis
Chun, P. I. F., & Lehman, H. K. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08802-9 · Cited by 41
Emerging Therapeutic Options for Chronic Pruritus
Reszke, R., Krajewski, P. K., & Szepietowski, J. C. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00534-y · Cited by 41
Hamie, L., Haddad, I., Nasser, N., Kurban, M., & Abbas, O. M. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00620-9 · Cited by 39
Puelles, J., Fofana, F., Rodriguez, D. N., Silverberg, J. I., Wollenberg, A., Barbosa, C. D., Vernon, M., Chavda, R., Gabriel, S., & Piketty, C. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20783 · Cited by 40
Self-citationNovel Targeted Biological Agents for the Treatment of Atopic Dermatitis
Yang, N., Chen, Z., Zhang, X., & Shi, Y. (2021) · BioDrugs · doi:10.1007/s40259-021-00490-x · Cited by 39
Childhood atopic dermatitis: current developments, treatment approaches, and future expectations
Çetinkaya, P. G., & Şahiner, Ü. M. (2019) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1810-105 · Cited by 45
Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies
Chu, C. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08799-1 · Cited by 37
Relative efficacy of systemic treatments for atopic dermatitis
Seger, E. W., Wechter, T., Strowd, L. C., & Feldman, S. R. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.09.053 · Cited by 38
Current pharmaceutical developments in atopic dermatitis
Misery, L., Huet, F., Gouin, O., Ständer, S., & Deleuran, M. S. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.12.003 · Cited by 39
The Impact of Air Pollution on Atopic Dermatitis
Lai, A., Owens, K. E., Patel, S., & Nicholas, M. W. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01095-w · Cited by 43
Dermatology today and tomorrow: from symptom control to targeted therapy
Blume‐Peytavi, U., Bagot, M., Tennstedt, D., Aroman, M. S., Stockfleth, E., Zlotogorski, A., Mengeaud, V., Schmitt, A.-M., Paul, C. F., Lim, H. W., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15335 · Cited by 38
Metadata
- Authors
- Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., Stewart, J., & Kabashima, K.
- Affiliations
- Jagiellonian University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-02
- Volume
- 376
- Issue
- 9
- Pages
- 826-835
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2593200577
- Cited by
- 592
- References
- 40
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 49 · 2023: 41 · 2022: 45 · 2021: 87 · 2020: 73 · 2019: 95 · 2018: 82 · 2017: 52
- FWCI
- 94.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, nemolizumab, pruritus, Eczema Area and Severity Index, body surface area involvement, treatment efficacy and safety, dose comparison, treatment discontinuation, adverse events, moderate-to-severe atopic dermatitis, adults, biologic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Edema, Female, Humans, Male, Middle Aged, Pruritus, Receptors, Interleukin, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.